HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

A 85380

structure given in first source; A-85380 is the S-enantiomer; A-159470 is the R-enantiomer

Also Known As:

3-(2-azetidinylmethoxy)pyridine; A 159470; A-159470; A-85380

Networked: 13 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azetines
    - Azetidines: 6
      - A 85380: 13

Experts

1.	Rueter, Lynne E: 3 articles (01/2006 - 06/2003)
2.	Ellis, J R: 2 articles (01/2009 - 09/2008)
3.	Mulligan, R S: 2 articles (01/2009 - 09/2008)
4.	Nathan, P J: 2 articles (01/2009 - 09/2008)
5.	Rowe, C C: 2 articles (01/2009 - 09/2008)
6.	Savage, G: 2 articles (01/2009 - 09/2008)
7.	Villemagne, V L: 2 articles (01/2009 - 09/2008)
8.	Wesnes, K A: 2 articles (01/2009 - 09/2008)
9.	Briggs, Clark A: 2 articles (01/2006 - 03/2005)
10.	Curzon, Peter: 2 articles (01/2006 - 06/2003)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2004 - "In dementia with Lewy bodies (DLB) reduced striatal 5-[(125)I]-A-85380 binding density, comparable to that in PD, may be a marker of early degeneration in nigrostriatal inputs, while in Alzheimer's disease (AD) reduced striatal 5-[(125)I]-A-85380 binding could be related to reduced cortical inputs. " 09/01/2008 - "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study." 01/01/2009 - "Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET." 01/01/2004 - "Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380."
2.	Acute Pain 12/01/1998 - "In the rat hot box test of thermal acute pain, both compounds produced antinociception, as indicated by an increase in the paw withdrawal latency, however EPIB was a approximately 33-fold more potent than A-85380 (ED50 = 0.004 and 0.11 micromol/kg, i.p., respectively). " 06/01/2003 - "In contrast, previous studies have demonstrated that blockade of central NNRs by prior administration of chlorisondamine (10 microg i.c.v.) prevents A-85380 induced anti-nociception indicating a predominantly central site of action of NNR agonists in relieving acute pain. "
3.	Dementia (Dementias) 01/01/2004 - "This in vitro autoradiography study describes the distribution of 5-[(125)I]-A-85380 binding in post-mortem brain tissue from normal elderly individuals and from cases with age-associated dementias of both neurodegenerative and vascular types. " 01/01/2006 - "5-[125I]-A-85380 binding, primarily reflecting the alpha4beta2 subtype, was compared in 16 DLB patients with DOC and 6 without DOC, matched for duration and severity of dementia. " 01/01/2004 - "In dementia with Lewy bodies (DLB) reduced striatal 5-[(125)I]-A-85380 binding density, comparable to that in PD, may be a marker of early degeneration in nigrostriatal inputs, while in Alzheimer's disease (AD) reduced striatal 5-[(125)I]-A-85380 binding could be related to reduced cortical inputs. " 01/01/2004 - "Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380."
4.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/01/2004 - "Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380."
5.	Parkinson Disease (Parkinson's Disease) 01/01/2004 - "In Parkinson's disease (PD), loss of striatal 5-[(125)I]-A-85380 binding closely parallels the loss of nigrostriatal dopaminergic markers previously observed. " 01/01/2004 - "Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380."

Related Drugs and Biologics

1.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
2.	Chlorisondamine (Chlorisondamine Chloride)
3.	Antisense Oligonucleotides
4.	Mecamylamine
5.	Ligands
6.	Galantamine (Galanthamine)
7.	Formaldehyde (Formol)
8.	Analgesics (Analgesic Drugs)
9.	ABT-202
10.	SIB1663

Related Therapies and Procedures

1.	Ligation
2.	Therapeutics
3.	Injections